Abstract
Background
The past years’ therapy for colorectal cancer has evolved rapidly with the introduction of novel cytotoxic agents such as irinotecan, capecitabine and oxaliplatin. Further advances have been achieved with the integration of targeted agents such as bevacizumab, cetuximab and recently, panitumumab. As a result, third-line treatment is now a necessary step in the optimal treatment of patients with metastatic colorectal cancer (MCRC).
Materials and methods
We conducted a literature review of English language publications on third-line therapy for MCRC from January 2000 to April 2007. Data on median overall survival (mOS), median time to progression (mTTP) and response rate were recorded.
Results
We found 27 articles and 22 abstracts to fulfil the criteria. Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months. With irinotecan and 5-FU, mOS around 8 months were reported and with cetuximab combined with irinotecan, the highest mOS was 9.8 months.
Conclusion
Third-line therapy in advanced colorectal cancer may improve mOS for patients with MCRC. Therefore, randomized studies should be conducted in the future.
Similar content being viewed by others
References
Cunningham D, Findlay M (1993) The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A(15):2077–2079
de Gramont A, Bosset J-F, Milan C, Rougier P, Bouché O, Etienne P-L, Marvan F, Louvet C, Guillot T, François E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15(2):808–815
Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammer H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413–1418
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138):1407–1412
de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33(2):214–219
Rothenberg ML, Oza AM, Bigelowe RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059–2069
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345
US Food and Drug Administration. www.FDA.gov
Rowland KM, Pitot HC, Sargent DJ, Philip PA, Mitchell EP, Mailliard JA, Goldberg RM, Alberts SR (2005) Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Proc ASCO, annual meeting, abstract no 3519
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658–1664
Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22(23):4753–4761
Salek T (2005) Oxaliplatin, bolus 5-fluorouracil (5-FU) and leucovorin (LV/b-FOL) in heavily pretreated patients with metastatic colorectal cancer. National Cancer Institute Slovakia, the first “b-FOL” experience. ESMO, abstract no 70
Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A (2001) Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 85(9):1258–1264
Abón G, Muňoz A, Rubio I, Manel MJ, Ferreiro J, Fernández R, Fuente N, López AG, Barceló R, López VG (2000) Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer. ESMO, abstract no 211P
Luppi G, Zanelli F, Di Stasi A, Bertolini F, Pifferi M (2002) Folfox 2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 88(4):270–272
Martoni A, Mini E, Pinto C, Nobili S, Gentile AL, Dentico P, Angelelli B, Scicolone S, Piana E, Mazzei T (2001) Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 12(4):519–524
Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R (2000) The value of oxaliplatin in combination with continuous infusion ± bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the study of digestive tract) cancer phase II trial. Tumori 86(6):465–469
Kallen K-J, Hofmann MAK, Timm A, Gödderz W, Galle PR, Heike M (2000) Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z Gastroenterol 38:153–157
Giacchetti S, Zidani R, Chollet P, Dogliotti L, Kunstlinger F, Le Rol A, Garufi C, Brienza S, Focan C, Bertheault-Cvitkovic F, Misset J, Lévi F (2000) Chronotherapy of metastatic colorectal cancer (MCC) with 5-fluorouracil (5-FU)-leucovorin (LV)-oxaliplatin (L-OHP) as second to seventh line treatment. Proc ASCO, annual meeting, abstract no 1255
Croles N, Smorenburg CH, van Groeningen CJ, Giaccone G, Boven E (2004) FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. Neth J Med 62(7/8):242–245
Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M (2002) Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 40:957–964
Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509–517
Gervais H, Artru P, Louvet C, Tournigand C, Maindrault F, Garcia M-L, de Gramont A (2002) Reintroduction of irinotecan in pretreated patients with metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 688
Kim HJ, Kwon HC, Kim SH, Kim JS (2003) Irinotecan with biweekly, low-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for oxaliplatin pretreated metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 1196
Maindrault F, Louvet C, André T, Gilles V, Artru P, Tournigand C, Garcia M, Gervais H, Carola E, Krulik M, de Gramont A (2001) Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR) Proc ASCO, annual meeting, abstract no 581
Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, Hegewald J, Mühldorfer S, Bittorf B, Hohenberger W, Hahn EG, Wein A (2003) Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 14(9):745–749
Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA (2006) Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 26(2B):1669–1672
Gubanski M, Naucler G, Almerud A, Lidestahl A, Lind P ARM (2005) Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 44(3):236–239
Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K (2005) Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56(1):10–14
Harba A, Jordan K, Kegel I, Behrens R, Grothey A, Schmoll HJ (2003) Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Proc ASCO, annual meeting, abstract no 1335
Chong G, Dickson JLB, Cunningham D, Norman RA, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N (2005) Capecitabine and mitomycin C as a 3rd line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93(5):510–514
Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB (2006) A phase II trial of oral S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan-and oxaliplatin containing regimens. Br J Cancer 95(12):1637–1641
Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch (2002) Raltitrexed (Tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study. Invest New Drugs 20:133–136
Garcia M, Gilles V, Louvet C, Defrance R, Tournigand C, Artru P, Maindrault-Goebel F, de Gramont A, Krulik M (2000) Bi-weekly irinotecan (CPT-11) combined with raltitrexed (“Tomudex”) treatment in heavily pre-treated patients with advanced colorectal cancer: a feasibility study. Proc ASCO, annual meeting, abstract no 987
Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L (2003) Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23(3C):2981–2985
Lonardi S, Paris MK, Stefani M, Caroti C, D’Amico M, Jirillo A, Pronzato P, Gallo L, Monfardini S, Aschele C (2004) Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Proc ASCO, annual meeting, abstract no 3577
Pachon V, Garcia-Alfonso P, Iglesias L, Siso I, Abad G, Khosravi P, Diaz V, Perez-Manga G (2005) Gemcitabine plus continuous infusion of 5-FU for heavily pretreated advanced colorectal cancer patients. Phase I/II study. Proc ASCO, annual meeting, abstract no 3735
Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke H-J, Pflüger K-H, Batran SAl, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C (2004) Prospective multicenter phase II study of irinotecan as third line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 15(5):473–477
Benavides M, García-Alfonso P, Cobo M, Muňoz-Martín A, Gil-Calle S, Carabantes F, Villar E, Graupera J, Balcells M, Pérez-Manga G (2004) Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Med Oncol 21(3):255–262
Gholam D, Giacchetti S, Brezault Bonnet C, Bouchahda M, Hauteville D, Adam R, Decot B, Ghémard O, Kustlinger F, Jasmin C, Levi F (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan-and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11(10):1072–1080
Polus M, Peeters M, Baert F, Vergauwe P, Kalantari H, Hendrickx K, Collignon J, van Maele P, Vandeputte L, van Laethem JL (2004) CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: a Belgian multicentre phase II study. Proc ASCO, annual meeting, abstract no 3716
Schulz J, Keller A, Canfield V, Parker G, Douglass E (2004) ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial. Am J Clin Oncol 27(4):337–342
Gollasch H, Gebauer B, Sturm I, Thuss-Patience P, Pink D, Stroszczynski C, Kretzschmar A (2004) Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox. Proc ASCO, annual meeting, abstract no 3695
Mirtsching B, Headlee C, Beasley S, Teel C, Jackson D (2004) Cetuximab single-agent activity in refractory metastatic colorectal cancer: single-center experience. Proc ASCO, annual meeting, abstract no 3703
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24(30):4914–4921
Mirtsching BC, Cichon J, Beasly S, Teel C, Jackson D, Headlee C (2005) Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patient and disease variables. Proc ASCO, gastrointestinal symposium, abstract no 205
Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94(6):792–797
Grande C, Mel JR, Salgado M, Reboredo M, Candamio S, Fernandez I, Quintero G, Huidobro G, Firvida JL, Valladares M (2006) Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Proc ASCO, annual meeting, abstract no 13551
Grothe W, Arnold D, Peinert S, Voigt W, Mantovani Loeffler L, Siewczynski R, Steps G, Boehme J, Graeven U, Schmoll H (2005) Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. Proc ASCO, annual meeting, abstract no 3669
Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24(21):3354–3360
Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W (2004) Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 8(Suppl 1):50–52
Peinert S, Arnold D, Grothe W, Lesske J, Siewczynski R, Schädlich B, Kegel T, Behrmann C, Schmoll H-J (2005) Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5fluorouracil, oxaliplatin, irinotecan, and cetuximab. ECCO abstract no 793
Dorligschaw O, Kegel T, Jordan K, Harba A, Grothey A, Schmoll H-J (2003) ZD1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 1494
Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D’Avirro P, Amado R (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3547
Berlin J, Neubauer M, Swanson P, Harker G, Burris H, Hecht JR, Navale L (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3548
Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Aqostara B, Barone C (2006) Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5(6):422–428
Levi F, Karaboue A, Jasmin C, Innominto P, Machover D, Kunstlinger F, Castagne V, Adam R, Guettier C, Bouchahda M (2005) Cetuximab reversal of chemotherapy resistance in patients with extensively pretreated metastatic colorectal cancer treated at Paul-Brousse hospital. ECCO abstract no 710
NCI 2007. www.cancer.gov. Health professional version
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22(2):229–237
Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48(3):265–277
Goetz MP, Grothey A (2004) Developments in combination chemotherapy for colorectal cancer. Expert Rev Anticancer Ther 4(4):627–637
Grothey A, Sargent D, Goldberg RM, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209–1214
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19(18):3801–3807
Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 16(9):2943–2952
Hejna M, Kornek GV, Raderer M, Depisch D, Brodowicz T, Fiebiger WC, Scheithauer W (1998) Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 78(6):760–764
www.Merck.de. 2006
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer J, Mitchell P, Alberts SR, Schwartz MA, Benson AB, Eastern Cooperative Oncology Group Study E3200 (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544
Saltz LB, Lenz H, Kindler H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Chen H (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO, Gastrointestinal Cancers Symposium, abstract no 169b
Hecht JR, Patnaik A, Malik I Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ (2004) ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc ASCO, annual meeting, abstract no 3511
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz H-J, Meropol NJ, Ramanathan RK, Becerra CHR, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1):38–50
Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzscmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll H-J (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 512
Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT (2002) A “modified de Gramont” regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87(4):393–399
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343(13):905–914
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22):3562–3569
Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11(11):1477–1483
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Antré T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-GO fashion advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400
Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11):2084–2091
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gundgaard, M.G., Soerensen, J.B. & Ehrnrooth, E. Third-line therapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 61, 1–13 (2008). https://doi.org/10.1007/s00280-007-0573-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0573-x